Literature DB >> 21751985

p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it.

Annette E Bowyer1, Anne Goodeve, Ri Liesner, Andrew D Mumford, Steve Kitchen, Mike Makris.   

Abstract

Haemophilia A is caused by a reduction in clotting factor VIII (FVIII). FVIII coagulant activity (FVIII:C) can be measured by three methods; the one-stage activated partial thromboplastin time-based clotting assay, the two-stage Xa generation-based clotting assay and the chromogenic Xa generation-based assay. The FVIII:C of most patients with haemophilia A are concordant regardless of the assay method employed. Up to a third of patients show assay discrepancy, usually with the two-stage and chromogenic assays being much lower than the one-stage assay. Very rarely, patients have been reported with lower one-stage compared to two-stage and chromogenic assays, but here we report that the mutation p.Tyr365Cys accounts for most of these patients and, at least in the UK, is not rare. We have identified this mutation in 23 different families. Affected male index individuals had a lower mean one-stage FVIII:C of 27 iu/dl compared to two-stage FVIII:C mean of 77 iu/dl. Affected individuals had minimal or absent bleeding symptoms and when these were present they were usually in patients with another co-inherited bleeding disorder. Affected individuals often had surgery without the need to correct the one-stage FVIII:C.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21751985     DOI: 10.1111/j.1365-2141.2011.08688.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.

Authors:  Annette E Bowyer; Joost J Van Veen; Anne C Goodeve; Steve Kitchen; Michael Makris
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

2.  The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority?

Authors:  Lisette M Schütte; Luca S Hodes; Iris van Moort; Sara C M Stoof; Frank W G Leebeek; Marjon H Cnossen; Moniek P M de Maat; Marieke J H A Kruip
Journal:  Haemophilia       Date:  2020-07-26       Impact factor: 4.287

Review 3.  An Update on Laboratory Diagnostics in Haemophilia A and B.

Authors:  Jens Müller; Wolfgang Miesbach; Florian Prüller; Thomas Siegemund; Ute Scholz; Ulrich J Sachs
Journal:  Hamostaseologie       Date:  2022-02-01       Impact factor: 2.145

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.